PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Tirzepatide

LY3298176; Mounjaro; Zepbound

Classification: GIP/GLP-1 dual incretin agonist

Mechanism: Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity

Benefits: Weight loss up to 20-22% (SURMOUNT); HbA1c reduction; BP and lipid improvement; cardiovascular benefit

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Mounjaro (tirzepatide) prescribing information
  2. FDA Zepbound (tirzepatide) prescribing information for chronic weight management
  3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. PMID 35658024

Loading interactive view…